Warfarin reversal: Consensus guidelines on behalf of the Australasian society of thrombosis and haemostasis

Medical Journal of Australia

Volumn 181, Issue 9, 2004, Pages 492-497

  Baker, Ross I ^a   Coughlin, Paul B ^b   Gallus, Alex S ^c   Harper, Paul L ^d   Salem, Hatem H ^b   Wood, Erica M ^e  

^a ROYAL PERTH HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c FLINDERS MEDICAL CENTRE   (Australia)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e AUSTRALIAN RED CROSS BLOOD SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMIODARONE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; FRESH FROZEN PLASMA; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; LOW MOLECULAR WEIGHT HEPARIN; PHYTOMENADIONE; PROTHROMBIN; PROTHROMBIN COMPLEX; PROTHROMBINEX HT; WARFARIN;

AGE; ARTICLE; ASIA; AUSTRALIA; BLEEDING; COMORBIDITY; CONSENSUS DEVELOPMENT; CONSULTATION; DENTAL SURGERY; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ELECTIVE SURGERY; HEMATOMA; HEMOSTASIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL STANDARD UNIT; MEDICAL EXPERT; MEDICAL SOCIETY; NEW ZEALAND; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PREOPERATIVE CARE; RISK FACTOR; SKIN SURGERY; THROMBOEMBOLISM;

EID: 8844227509     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb06407.x     Document Type: Article

References (38)

1. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant therapy. Chest 1998; 114: 511S-523S.
2. Gallus AS, Baker RI, Chong BH, et al. Consensus guidelines for warfarin therapy. Med J Aust 2002; 172: 600-605.
3. Australian pharmaceutical index. Sydney: IMS Health, January 2004.
4. Boots Healthcare Australia. Coumadin. Australian product information. Sydney: Boots Healthcare Australia Pty Ltd, 26 July 2000.
5. Majerus PW, Broze GJ, Miletich JP, et al. Anticoagulant thrombolytic, and antiplatelet drugs. In: Hardman JG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996: 1347-351.
6. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119: 8S-21S.
7. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5mg and 10mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126: 133-136.
8. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-138.
9. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
10. Campbell P, Roberts G, Eaton V, et al. Managing warfarin therapy in the community. Aust Prescriber 2001; 24: 86-89.
11. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428.
12. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomised trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin.Ann Neurol 1997; 42: 857-865.
13. Fitzmaurice D, Blann A, Lip GYH. Bleeding risks of antithrombotic therapy. BMJ 2002; 325: 828-831.
14. Landefeld S, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction and prevention. Am J Med 1993; 95: 315-328.
15. van der Meer FJM, Rosendaal FR, Vanderbroucke JP, et al. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med 1993; 153: 1557-1562.
16. Levine MN, Raskob G, Landefeld S, et al. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119: 108S-121S.
17. Institute for Clinical Systems Improvement. Health Care Guideline Supplement. Anticoagulation therapy supplement 2003. Available at: www.icsi.org (accessed Feb 2004).
18. Hirsh J, Dalen JE, Deykin D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1995; 108: 231S-246S.
19. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight-heparin for outpatient treatment of acute venous thromboembolism. Ann Intern Med 2003; 138: 714-719.
20. Tait RC, Sefcick A. A warfarin induction regimen for out-patient anticoagulation in patients with atrial fibrillation. Br J Haematol 1998; 101: 450-454.
21. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159: 46-48.
22. Stein PD, Alpert JS, Bussey HI, et al. Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001; 119: 2205-2275.
23. Vink R, Kraaijenhagen RA, Hutten BA, et al. The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a metaanalysis. J Am Coll Cardiol 2003; 42: 2042-2048.
24. Kearon C, Ginsberg JS, Kovacs MJ, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-639.
25. Hyleck EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349: 1019-1026.
26. Perret-Guillaume C, Wahl DG. Low-dose warfarin in atrial fibrillation leads to more thromboembolic events without reducing major bleeding when compared with adjusted dose. A meta-analysis. Thromb Haemost 2004; 91: 394-402.
27. Australian Red Cross Blood Service. Transfusion medicine manual 2003. Available at: www.arcbs.redcross.org.au/ARCBS (accessed Feb 2004).
28. Ansell J, Dalen J, Bussey H, et al. Managing oral anticoagulant therapy. Chest 2001; 119: 22S-38S.
29. Roche Products. Konakion. Australian product information. Sydney: Roch Products Pty Ltd, 12 February 1998 (tablets and MM ampoules); 18 October 2000 (MM Paediatric).
30. Soedirman JR, De Bruijn EA, Maes RA, et al. Pharmacokinetics and tolerance of intravenous and intramuscular phylloquinone (Vitamin K1) mixed micelles formulation. Br J Clin Pharmacol 1996; 41: 517-523.
31. Raj G, Kumar R, McKinney WP. Time course of reversal of anticoagulant effect of warfarin by intravenous and subcutaneous phytonadione. Arch Intern Med 1999; 159: 2721-2724.
32. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med 1998; 158: 2136-2140.
33. Crowther MA, Douketic JD, Schnurr T, et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: a randomized controlled trial. Ann Intern Med 2002; 137: 251-254.
34. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anesth 2002; 49: S11-S25.
35. CSL. Prothrombinex-HT Australian product information. Version 2.00. Melbourne: CSL Bioplasma, September 2002.
36. Australian Red Cross Blood Service. Circular of information 2003. Available at: www.arcbs.redcross.org.au (accessed Feb 2004).
37. CSL. Prothrombinex-HT New Zealand product information. Version 6.00. CSL Bioplasma, June 2002.
38. New Zealand Blood Service. Transfusion medicine handbook 2003. Available at: www.nzblood.co.nz (accessed June 2004).